Research Information System
Pituitary, vol.22, no.4, pp.387-396, 2019 (SCI-Expanded, Scopus)
PurposeTo investigate the effects of preoperative somatostatin analogue (SSA) treatment on the annual cost of all acromegaly treatment modalities and on remission rates.MethodsThe medical records of 135 patients with acromegaly who were followed at endocrinology clinic of Cerrahpasa Medical Faculty for at least 2years after surgery between 2009 and 2016 were reviewed.ResultsThe mean follow-up time was 50.925.7months. Early remission was defined according to 3rd month values in patients who didn't achieve remission, and 6th month values in patients who achieved remission at the 3rd month after surgery. The early and late remission rates of the entire study population were 40% and 80.7%, respectively. The early remission of the preoperative SSA-treated group (61.5%) was significantly higher than SSA-untreated group (31.2%) (p=0.002). The early remission of the preoperative SSA-treated patients with macroadenomas (52.2%) was also significantly higher than the SSA-untreated group (23.5%) (p=0.02). In the subgroup analysis; this difference was much more pronounced in invasive macroadenomas (p=0.002). There were no differences between the groups in terms of late remission.The median annual cost of all acromegaly treatment modalities in study population was Euro3788.4; the cost for macroadenomas was significantly higher than for microadenomas (Euro4125.0 vs. Euro3226.5, respectively; p=0.03). Preoperative SSA use in both microadenomas and macroadenomas didn't alter the cost of treatment. The increase in the duration of preoperative medical treatment had no effect on early or late remissions (p=0.09; p=0.8).Conclusions Preoperative medical treatment had no effect on the costs of acromegaly treatment. There was a benefical effect of pre-operative SSA use on early remission in patients with macroadenomas; however, this effect didn't persist long term.